Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program-Reference-Cited by-同舟云学术

Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program

Published:2014-11 Issue:5 Volume:61 Page:976-983
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Colombo Massimo,Strasser Simone,Moreno Christophe,Abrao Ferreira Paulo,Urbanek Petr,Fernández Inmaculada,Abdurakmonov Djamal,Streinu-Cercel Adrian,Verheyen Anke,Iraqi Wafae,DeMasi Ralph,Hill Andrew,Lonjon-Domanec Isabelle,Wedemeyer Heiner

Publisher

Elsevier BV

Subject

Hepatology

Reference39 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

3. Aging of Hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression;Davis;Gastroenterology,2010

4. Interferon therapy prolonged life expectancy among chronic hepatitis C patients;Yoshida;Gastroenterology,2002

5. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study;Bruno;Hepatology,2007

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era;World Journal of Gastroenterology;2023-04-07

2. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C;World Journal of Gastroenterology;2023-02-14

3. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments;Expert Opinion on Pharmacotherapy;2017-11-22

4. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?;Journal of Comparative Effectiveness Research;2017-01

5. Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy;Reviews on Recent Clinical Trials;2016-10-04